Signs and symptoms articles within Nature Reviews Clinical Oncology

Featured

• Research Highlight | 16 January 2018

  First-in-class HIF2α antagonist safe and effective

  • Peter Sidaway

• Research Highlight | 25 August 2015

  Rolapitant—a new and safer antiemetic agent

  • Diana Romero

• Review Article | 12 August 2014

  Cancer-related fatigue—mechanisms, risk factors, and treatments

  Fatigue is one of the most common adverse effects of cancer that might persist for years after treatment completion. Among the biological mechanisms underlying cancer-related fatigue, inflammation processes have a key role in the development and persistence of this symptom. In addition, genetic, biological, psychosocial, and behavioural risk factors are also associated with the occurrence of cancer-related fatigue. This Review describes the mechanisms, risk factors, and possible interventions for cancer-related fatigue.

  • Julienne E. Bower

• Research Highlight | 03 June 2014

  NEPA—a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting

  • Alessia Errico

• Review Article | 13 November 2012

  Imaging hypoxia to improve radiotherapy outcome

  Hypoxia can affect clinical outcome after radiotherapy, resulting in reduced local tumour control and increased malignant progression. Hence, its detection is of utmost importance, but how can we detect hypoxia? Horsman et al. assess the potential use of imaging to identify hypoxic tumours that would lead to treatment modifications with the aim of improving clinical outcome after radiotherapy.

  • Michael R. Horsman
  • , Lise Saksø Mortensen
  •  & Jens Overgaard

• News & Views | 14 August 2012

  Cetuximab dosing by rash—is the scaling of EVEREST meaningful?

  The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed, data from the ongoing EVEREST II trial must be awaited before dose escalation can be considered for clinical use.

  • Sebastian Stintzing
  •  & Heinz-Josef Lenz

• Review Article | 24 April 2012

  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

  Cancer cells rely on angiogenesis to fulfil their need for oxygen and nutrients; hence, agents targeting angiogenic pathways and mediators have been investigated as potential cancer drugs. However, a significant number of patients either do not respond to antiangiogenic agents or fairly rapidly develop resistance to them, which raises questions about how resistance develops and how it can be overcome. In this Review, the authors examine the evidence linking antiangiogenic agents and intratumour hypoxia by providing an overview of the preclinical and clinical data, focusing on the possibility of exploiting intratumour hypoxia as a means to improve the therapeutic response to antiangiogenic agents.

  • Annamaria Rapisarda
  •  & Giovanni Melillo

• In Brief | 27 March 2012

  High intake of omega-3 PUFAs reduces fatigue in survivors

• Review Article | 16 March 2010

  Treatment of painful bone metastases

  Painful bone metastases can be treated with radiotherapy, and single-fraction radiotherapy with 1 × 8 Gy has been shown to be as effective for pain relief as multi-fraction regimens. The authors discuss why single-fraction radiotherapy is considered the standard regimen for uncomplicated painful bone metastases without pathological fractures or spinal cord compression, and highlight the reasons why long-course multi-fraction radiotherapy should be reserved for patients with a relatively favorable survival prognosis.

  • Dirk Rades
  • , Steven E. Schild
  •  & Janet L. Abrahm